tiprankstipranks
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksStock ScreenerCompare StocksPenny Stock ScreenerTop Product Insights Stocks
Daily Updates
Daily Analyst RatingsTrending StocksTop Stock GainersTop Stock LosersMost Active StocksDividend StocksChatGPT Stocks
New
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarMarket Holidays
ETF Research Tools
ETF CenterETF Screener
New
Compare ETFsTop ETFs by AUM
ETFs On the Move
Top ETF GainersTop ETF LosersMost Active ETFs
ETF Ideas
S&P 500 Index ETFsNasdaq 100 Index ETFsS&P 500 Sector ETFsBond ETFsCommodity ETFsCurrency ETFsIndustry ETFs
Best Dividend StocksBest High Yield Dividend StocksDividend Stock ComparisonDividend Calculator
Popular
Dividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
My PortfolioMy WatchlistMy PerformanceMy Portfolio AnalysisCrowd Insights
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
Education
TipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityCareersContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
ETF Research Tools
ETF Center
ETF Screener
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Crypto Center
Bitcoin
Ethereum
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
Newsletter Center
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
Plans & Pricing

PGEN Stock Latest News

Precigen Reports First Quarter 2023 Financial Results and Business Updates
Press ReleasesPrecigen Reports First Quarter 2023 Financial Results and Business Updates
21d ago
PGEN
PGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Pre-EarningsPGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
23d ago
PGEN
Precigen’s UltraCAR-T platform shows antitumor eefficacy in preclinical data
The FlyPrecigen’s UltraCAR-T platform shows antitumor eefficacy in preclinical data
1M ago
PGEN
Precigen amends exclusive license agreement with Alaunos Therapeutics
The FlyPrecigen amends exclusive license agreement with Alaunos Therapeutics
2M ago
PGEN
TCRT
Precigen: First patient dosed in Phase 1/1b study of of PRGN-3007
The FlyPrecigen: First patient dosed in Phase 1/1b study of of PRGN-3007
2M ago
PGEN
Precigen reports Q4 EPS (11c), consensus (10c)
The FlyPrecigen reports Q4 EPS (11c), consensus (10c)
3M ago
PGEN
Precigen options imply 35.3% move in share price post-earnings
The FlyPrecigen options imply 35.3% move in share price post-earnings
3M ago
PGEN
3 Stocks Insiders Love
Stock Analysis & Ideas3 Stocks Insiders Love
4M ago
PGEN
TNYA
Precigen price target raised to $10 from $7 at Cantor Fitzgerald
The FlyPrecigen price target raised to $10 from $7 at Cantor Fitzgerald
4M ago
PGEN
Biotech Alert: Searches spiking for these stocks today
The FlyBiotech Alert: Searches spiking for these stocks today
4M ago
ARDS
CYTO
Precigen 42.86M share Spot Secondary priced at $1.75
The FlyPrecigen 42.86M share Spot Secondary priced at $1.75
4M ago
PGEN
Precigen $75M Spot Secondary; price range $1.75-$1.85
The FlyPrecigen $75M Spot Secondary; price range $1.75-$1.85
4M ago
PGEN
Precigen announces $75M common stock offering
The FlyPrecigen announces $75M common stock offering
4M ago
PGEN
Precigen reports results from Phase 1 PRGN-2012 study
The FlyPrecigen reports results from Phase 1 PRGN-2012 study
4M ago
PGEN
Precigen to host virtual research and development day
The FlyPrecigen to host virtual research and development day
4M ago
PGEN
Precigen to host virtual research and development day
The FlyPrecigen to host virtual research and development day
4M ago
PGEN
Precigen to host virtual research and development day
The FlyPrecigen to host virtual research and development day
4M ago
PGEN
Precigen CEO says will focus on clinical programs’ path to licensure in 2023
The FlyPrecigen CEO says will focus on clinical programs’ path to licensure in 2023
5M ago
PGEN
Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks
The FlyCantor calls Merck top large cap pharma pick, names 8 SMID cap top picks
5M ago
MRK
ACRS
Precigen announces ‘positive’ Phase 1 dose escalation data from PRGN-3006 study
The FlyPrecigen announces ‘positive’ Phase 1 dose escalation data from PRGN-3006 study
6M ago
PGEN
Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs
Press ReleasesPrecigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs
7M ago
PGEN
Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics
Press ReleasesPrecigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics
9M ago
PGEN